Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00124891 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
NCT00124891 is a Phase 2 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 500 participants.
The verdict
NCT00124891, a Phase 2 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
Study Summary
To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or myocardial infarction without ST elevation).
Interventions
- DRUG Double-blind investigational anti-arrhythmic
- DRUG GAP-486
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2005-06-01 |
| Est. Completion | 2006-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00124891
The ClinicalTrials.gov registry entry for NCT00124891 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Double-blind investigational anti-arrhythmic is the first listed.
NCT00124891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00124891 about?
NCT00124891 is a clinical study titled "Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia". To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or myocardial infarction without ST elevation).
What is the current status of trial NCT00124891?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2005-06-01. Estimated completion is 2006-11-01.
What interventions are being tested in trial NCT00124891?
The interventions under investigation include: Double-blind investigational anti-arrhythmic (DRUG), GAP-486 (DRUG).
Who is sponsoring clinical trial NCT00124891?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.